Table 3. Univariable Analysis of Factors Associated With Progression After PRRT.
| HR (95% CI) | P value | |
|---|---|---|
| Age at diagnosis, median (IQR), y | 1.00 (0.86-1.04) | .92 |
| Age at first PRRT, median (IQR), y | 0.99 (0.95-1.03) | .49 |
| Men | 0.76 (0.34-1.69) | .50 |
| NET primary location | ||
| Pancreas | 1 [Reference] | NA |
| Small bowel | 0.19 (0.07-0.55) | .01 |
| Other or unknown | 0.68 (0.28-1.66) | .39 |
| Grade of NET | ||
| 1 | 1 [Reference] | NA |
| 2 | 1.13 (0.41-3.12) | .81 |
| 3 | 2.57 (0.72-9.17) | .15 |
| Systemic therapy prior to PRRT | 1.13 (0.51-2.52) | .77 |
| Liver-directed therapy prior to PRRT | 0.71 (0.32-1.57) | .40 |
| Hepatic resection | 0.90 (0.38-2.16) | .81 |
| Radiofrequency ablation | 0.53 (0.07-3.92) | .53 |
| Bland embolization | 0.88 (0.26-2.99) | .84 |
| Transarterial chemoembolization | 0.69 (0.24-2.02) | .50 |
| Transarterial radioembolization | 0.90 (0.31-2.63) | .85 |
| Prior resection of primary tumor | 0.76 (0.33-1.78) | .53 |
Abbreviations: HR, hazard ratio; IQR, interquartile range; NA, not applicable; NET, neuroendocrine tumor; PRRT, peptide receptor radionuclide therapy.